6CM
EVLO

683 Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

683 Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,515
Closed -$145K – 343
2022
Q4 		$145K Buy
+4,515
New +$179K 0.01% 223

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

683 Capital Management's EVLO Position: Q1 2023 in Review

683 Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 4,515 shares — an estimated $145K sold.

683 Capital Management first reported a position in EVLO in Q4 2022 and held it in 1 quarter. The position peaked at $145K in Q4 2022. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • 683 Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 4,515 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $145K.
  • 683 Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • 683 Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $145K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.